cbdMD Welcomes Senate Spending Bill Ensuring Access to CBD Products
cbdMD, Inc. has recently welcomed the newly proposed Senate spending bill, which is aimed at protecting access to full-spectrum CBD and other natural hemp products. The Senate Appropriations Committee revealed the text of a continuing resolution on August 2, which serves to fund federal agencies through December 11. A significant aspect of this bill is its provision to postpone the impending federal restrictions on various hemp products, which were initially set to come into effect on November 12. This delay is seen as a potential game-changer for the hemp industry, with many stakeholders, including the U.S. Hemp Roundtable, labeling this as a landmark victory, arguably the most significant since the passing of the 2018 Farm Bill that legalized hemp cultivation.
The intended extension of the current federal framework aims to temporarily shield naturally derived hemp products, while still addressing specific synthetic cannabinoids that do not occur naturally in the Cannabis sativa L. plant, which will remain subject to the original timeline. cbdMD, whose portfolio largely consists of naturally derived full-spectrum CBD and other hemp products, finds itself well within the scope of what the Senate's text seeks to protect.
It’s crucial to note that as of now, the Senate text is not official law. The House previously passed a version of the continuing resolution which lacked these hemp provisions. Therefore, it is imperative that this language is preserved in the final legislative actions by both the House and Senate and that it is signed by the President to become effective. cbdMD has pledged to keep a close watch on this legislative process.
T. Ronan Kennedy, CEO of cbdMD, stated, "This is a bridge, not the finish line. It is certainly an encouraging move for our industry and our consumers." He emphasized that for the first time, protections for naturally derived hemp products have found their way into the base text of a crucial spending bill, rather than being relegated to an amendment that must fight for a vote. Should the bill pass, it could help maintain access to full-spectrum CBD products that countless Americans depend upon while allowing the industry to engage further with Congress to develop permanent and sensible regulations.
The notion of the proposed extension is not viewed as merely a new compliance deadline but a chance to keep discussions on hemp alive through December 11. This opens a pathway for lawmakers to potentially integrate a more sustainable regulatory framework into broader legislative measures like the Farm Bill or omnibus appropriations package. The progress made follows extensive consultations between businesses, farmers, consumers, advocates, and the public, bolstered by backing from the White House in support of continued access to full-spectrum CBD.
As a leader in the hemp-derived wellness sector, cbdMD produces products that adhere to rigorous third-party testing and quality assurance protocols. They actively endorse both federal and state initiatives aimed at establishing consistent standards for the production, testing, labeling, and responsible distribution of hemp-derived wellness items.
Founded in Charlotte, North Carolina, cbdMD, Inc. is recognized for its production and distribution of premium hemp-derived cannabidiol products, including its prominent cbdMD, Bluebird Botanicals, Herbal Oasis, and Paw CBD brands. The firm's mission is to elevate customer well-being through innovative and carefully formulated products that are supported by independent testing. For further details, please visit www.cbdmd.com.
This report contains forward-looking statements as defined by the U.S. Private Securities Litigation Reform Act of 1995. Specific words such as "believe," "expect," "would," and other similar expressions are included to identify these forward-looking statements, which are reliant on management's current anticipations and are susceptible to various risks. These uncertainties could include fluctuating timelines, legislative outcomes, and any alterations to the hemp provisions prior to their enactment. The actual implications may differ significantly from these expectations, and cbdMD undertakes no obligation to update any forward-looking statements as mandated by law. It is vital to note that this report does not constitute legal, regulatory, or investment guidance, and there can be no guarantee that the proposed legislation will indeed be enacted or lead to any specific regulatory results.
The intended extension of the current federal framework aims to temporarily shield naturally derived hemp products, while still addressing specific synthetic cannabinoids that do not occur naturally in the Cannabis sativa L. plant, which will remain subject to the original timeline. cbdMD, whose portfolio largely consists of naturally derived full-spectrum CBD and other hemp products, finds itself well within the scope of what the Senate's text seeks to protect.
It’s crucial to note that as of now, the Senate text is not official law. The House previously passed a version of the continuing resolution which lacked these hemp provisions. Therefore, it is imperative that this language is preserved in the final legislative actions by both the House and Senate and that it is signed by the President to become effective. cbdMD has pledged to keep a close watch on this legislative process.
T. Ronan Kennedy, CEO of cbdMD, stated, "This is a bridge, not the finish line. It is certainly an encouraging move for our industry and our consumers." He emphasized that for the first time, protections for naturally derived hemp products have found their way into the base text of a crucial spending bill, rather than being relegated to an amendment that must fight for a vote. Should the bill pass, it could help maintain access to full-spectrum CBD products that countless Americans depend upon while allowing the industry to engage further with Congress to develop permanent and sensible regulations.
The notion of the proposed extension is not viewed as merely a new compliance deadline but a chance to keep discussions on hemp alive through December 11. This opens a pathway for lawmakers to potentially integrate a more sustainable regulatory framework into broader legislative measures like the Farm Bill or omnibus appropriations package. The progress made follows extensive consultations between businesses, farmers, consumers, advocates, and the public, bolstered by backing from the White House in support of continued access to full-spectrum CBD.
As a leader in the hemp-derived wellness sector, cbdMD produces products that adhere to rigorous third-party testing and quality assurance protocols. They actively endorse both federal and state initiatives aimed at establishing consistent standards for the production, testing, labeling, and responsible distribution of hemp-derived wellness items.
About cbdMD, Inc.
Founded in Charlotte, North Carolina, cbdMD, Inc. is recognized for its production and distribution of premium hemp-derived cannabidiol products, including its prominent cbdMD, Bluebird Botanicals, Herbal Oasis, and Paw CBD brands. The firm's mission is to elevate customer well-being through innovative and carefully formulated products that are supported by independent testing. For further details, please visit www.cbdmd.com.
Forward-Looking Statements
This report contains forward-looking statements as defined by the U.S. Private Securities Litigation Reform Act of 1995. Specific words such as "believe," "expect," "would," and other similar expressions are included to identify these forward-looking statements, which are reliant on management's current anticipations and are susceptible to various risks. These uncertainties could include fluctuating timelines, legislative outcomes, and any alterations to the hemp provisions prior to their enactment. The actual implications may differ significantly from these expectations, and cbdMD undertakes no obligation to update any forward-looking statements as mandated by law. It is vital to note that this report does not constitute legal, regulatory, or investment guidance, and there can be no guarantee that the proposed legislation will indeed be enacted or lead to any specific regulatory results.
Topics Consumer Products & Retail）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.